Literature DB >> 14582047

Serum leptin in dialysis renal osteodystrophy.

Giorgio Coen1, Paola Ballanti, Maria Stephanie Fischer, Alessandro Balducci, Santo Calabria, Luisa Colamarco, Giacomo Di Zazzo, Francesca Lifrieri, Micaela Manni, Daniela Sardella, Italo Nofroni, Ermanno Bonucci.   

Abstract

BACKGROUND: The hormone leptin is considered to have a role in the prevention of osteoporosis and probably acts on bone tissue through inhibition of osteoclasia. Its action has been attributed to interference in osteoprotegerin (OPG)/OPG-ligand equilibrium. Contradictory data also have been reported, casting doubts on the positive effect on bone mass of the hormone, at least in males. To date, the relation between serum leptin levels of dialysis patients and renal osteodystrophy, defined by histomorphometric and histodynamic parameters of bone, has not been studied.
METHODS: The study included 46 hemodialysis patients (32 men, 14 women; age, 57.2 +/- 11.4 years). A transiliac bone biopsy after double-tetracycline labeling was performed for histological, histomorphometric, and histodynamic studies. Blood samples were drawn for leptin, intact parathyroid hormone (PTH), whole PTH (PTH1-84), OPG, bone alkaline phosphatase, calcium, phosphate, 25-hydroxycholecalciferol, and calcitriol. Serum leptin was measured by means of a radioimmunoassay.
RESULTS: Eighteen patients had mixed osteodystrophy (MO); 17 patients, hyperparathyroidism; 9 patients, adynamic bone disease (ABD); and 2 patients, osteomalacia. Aluminum histochemistry results were positive in 1 patient with ABD and 1 patient with MO. A sex difference was found in serum leptin levels (48.9 +/- 38 ng/mL in women and 12.2 +/- 13.2 ng/mL in men; P < 0.0002). In the entire population, lnleptin correlated significantly with body mass index (BMI; P < 0.01). SD score (SDS) leptin (adjusted for BMI, sex, and age) correlated inversely with PTH1-84 level and osteoclastic surface (OcS/BS; P < 0.05) and had a borderline correlation with bone formation rate. Correlations between leptin levels and other parameters were enhanced in men. SDS leptin correlated inversely with OcS/BS (P < 0.01), osteoclastic number (P < 0.01), and mineral apposition rate (P < 0.01). In addition, SDS leptin had a borderline inverse correlation with osteoblast surface (P < 0.06) and significant correlation with OPG level (P < 0.05). No difference was found in serum leptin levels between histological groups.
CONCLUSION: The reported data confirm the finding of a positive relation between serum leptin level and BMI and greater levels in women compared with men. Serum leptin level is connected to bone resorption and also bone formation, both inversely related to serum leptin levels. The decrease in osteoclasia that accompanies increasing serum leptin levels does not seem to be related to an enhanced OPG effect because it was accompanied by decreased OPG levels. Low-turnover bone disease does not appear to be caused by increased serum leptin levels. The nature of the interrelation between serum leptin and PTH1-84 levels requires further study.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14582047     DOI: 10.1016/j.ajkd.2003.07.005

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

Review 1.  Leptin in chronic kidney disease: a link between hematopoiesis, bone metabolism, and nutrition.

Authors:  Jingjing Zhang; Ningning Wang
Journal:  Int Urol Nephrol       Date:  2013-12-14       Impact factor: 2.370

Review 2.  The intriguing connections of leptin to hyperparathyroidism.

Authors:  Stergios A Polyzos; Leonidas Duntas; Jens Bollerslev
Journal:  Endocrine       Date:  2017-07-20       Impact factor: 3.633

3.  Correction of metabolic acidosis in hemodialysis: consequences on serum leptin and mineral metabolism.

Authors:  Alessandra M Bales; Rosa M A Moysés; Luciene M dos Reis; Fabiana G Graciolli; James Hung; Manuel Carlos Martins Castro; Rosilene M Elias
Journal:  Int Urol Nephrol       Date:  2014-09-25       Impact factor: 2.370

4.  The effect of leptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and Wnt inhibitors in young women with hypothalamic amenorrhea.

Authors:  Joo-Pin Foo; Stergios A Polyzos; Athanasios D Anastasilakis; Sharon Chou; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2014-08-22       Impact factor: 5.958

5.  Associations between serum leptin level and bone turnover in kidney transplant recipients.

Authors:  Csaba P Kovesdy; Miklos Z Molnar; Maria E Czira; Anna Rudas; Akos Ujszaszi; Laszlo Rosivall; Miklos Szathmari; Adrian Covic; Andras Keszei; Gabriella Beko; Peter Lakatos; Janos Kosa; Istvan Mucsi
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-05       Impact factor: 8.237

Review 6.  Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?

Authors:  Doris Wagner; Astrid Fahrleitner-Pammer
Journal:  Wien Med Wochenschr       Date:  2010-08-16

7.  Relation of leptin and adiponectin with cardiovascular risk factors, intact parathormone, and vitamin D levels in patients with primary hyperparathyroidism.

Authors:  Daniel Antonio de Luis; Gonzalo Diaz Soto; Rosa Conde; Olatz Izaola; Beatriz de la Fuente
Journal:  J Clin Lab Anal       Date:  2012-09       Impact factor: 2.352

8.  Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD.

Authors:  Gérard M London; Sylvain J Marchais; Alain P Guérin; Pierre Boutouyrie; Fabien Métivier; Marie-Christine de Vernejoul
Journal:  J Am Soc Nephrol       Date:  2008-05-14       Impact factor: 10.121

9.  Obesity hypertension: the regulatory role of leptin.

Authors:  Shilpa Kshatriya; Kan Liu; Ali Salah; Tamas Szombathy; Ronald H Freeman; Garry P Reams; Robert M Spear; Daniel Villarreal
Journal:  Int J Hypertens       Date:  2011-01-03       Impact factor: 2.420

Review 10.  The impact of inflammation on bone mass in children.

Authors:  Wai W Cheung; Jian-Ying Zhan; Kyung Hoon Paik; Robert H Mak
Journal:  Pediatr Nephrol       Date:  2011-01-01       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.